In a report released today, Vamil Divan from Credit Suisse maintained a Buy rating on Johnson & Johnson (JNJ – Research Report), with a price target of $152. The company’s shares opened today at $139.
According to TipRanks.com, Divan has currently no stars on a ranking scale of 0-5 stars, with an average return of -4.0% and a 41.2% success rate. Divan covers the Healthcare sector, focusing on stocks such as Teva Pharmaceutical Industries Limited, Aimmune Therapeutics, and Ironwood Pharma.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Johnson & Johnson with a $147 average price target, implying a 5.8% upside from current levels. In a report issued on April 10, RBC Capital also reiterated a Buy rating on the stock with a $144 price target.
Johnson & Johnson’s market cap is currently $367.5B and has a P/E ratio of 24.60. The company has a Price to Book ratio of 6.15.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.